Insights from Michele Stokes, VP APAC & GM, PCI Melbourne
Q: You’ve spent more than two decades in the CDMO industry. How has that shaped your perspective on clinical supply today?
Michele Stokes:
My background spans the full CDMO lifecycle—from early clinical trials through to commercial packaging—and across multiple geographies, including more than 15 years working in APAC. That breadth gives me a very practical view of what sponsors actually need: speed, compliance, and flexibility, without sacrificing visibility or control.
Clinical development today is far more global and complex than it was even a decade ago. Sponsors are managing multiple regulators, time zones, and supply chains simultaneously. The CDMOs that succeed are the ones that can reduce friction across that complexity, not add to it.
Q: For sponsors unfamiliar with PCI Melbourne, how would you define the site’s core role within global clinical development?
Michele Stokes:
At its core, PCI Melbourne is a clinical trial supply specialist, supporting GMP labeling, kitting, packaging, authorized person (AP) release, storage, and direct-to-site distribution. But strategically, our role is much bigger than that.
We function as a gateway between the US, Europe, and APAC. For US and European sponsors, Australia is often the most efficient entry point into the Asia-Pacific region. Conversely, for APAC-based companies, Melbourne is an ideal stepping stone into Western markets. That bidirectional capability is becoming increasingly important as development pathways globalize earlier.
Q: Why is Australia—particularly Melbourne—so attractive for early-phase clinical trials?
Michele Stokes:
Australia offers a rare combination of regulatory speed, operational flexibility, and financial incentives.
From a regulatory standpoint, the TGA’s Clinical Trial Notification (CTN) pathway allows sponsors to initiate Phase I studies faster and with fewer upfront documentation requirements than many other regions. Critically, investigational product can be imported, labeled, and prepared before final trial approval—something that’s not possible in the US.
Operationally, Australia has world-class Phase I units, highly experienced investigators, and a diverse patient population. Financially, the R&D tax incentive—up to ~43% rebate on eligible clinical trial activity—makes Australia not just fast, but economically compelling.
Q: How is Australia’s role in global clinical development changing?
Michele Stokes:
Historically, Australia and APAC were often added later in global trials. What we’re now seeing is a meaningful shift: Australia is increasingly the starting point.
One major driver is manufacturing geography. More investigational products are being manufactured in China. Australia is uniquely positioned to import that material efficiently, perform GMP labeling and packaging locally, and initiate Phase I trials quickly—often before sponsors are ready to activate sites in the US or Europe.
That shift puts Australia squarely at the front end of global development, not the back.
Q: Biologics and cold chain complexity are growing fast. How is PCI Melbourne responding?
Michele Stokes:
We’re seeing a clear increase in biologics, which translates directly into more ultra-low temperature requirements. In response, we’ve expanded our -80°C freezer capacity, added liquid nitrogen storage, and invested in infrastructure that allows labeling at cold temperatures without compromising operator efficiency.
One example is the introduction of chiller tables, which allow products to remain at 2–8°C while operators work in ambient conditions. This improves compliance, throughput, and staff safety—all critical as protocols become more temperature-sensitive.
Q: What truly differentiates PCI Melbourne from other clinical supply providers in Australia?
Michele Stokes:
There are three key differentiators.
- Scale and capacity. We operate a large, purpose-built facility with significant available capacity across ambient, refrigerated, frozen, and ultra-low storage—something that’s increasingly rare.
- Regulatory depth. We have two dedicated Authorized Persons on site, enabling full AP release for Phase II and above studies. Not all providers in Australia can offer this, and it’s essential for compliance under TGA and PIC/S guidance.
- Digital visibility. Our Bridge inventory management platform gives sponsors 24/7, real-time access to inventory, shipments, and ordering—regardless of time zone. For global teams managing studies across continents, that level of transparency is a game changer.
Q: Authorized Person (AP) release can be confusing for global sponsors. Why does this matter?
Michele Stokes:
AP release is a regulatory requirement for Phase II and above trials in Australia and most of APAC. It’s comparable to the QP process in Europe and fundamentally different from the US model, where sponsors often retain final release responsibility.
The key point is this: you cannot outsource AP release unless the site itself holds the appropriate GMP license and authorized personnel. Sponsors who overlook this risk running non-compliant trials without realizing it.
PCI Melbourne has deep experience here, with dedicated APs embedded into our GMP systems. That expertise removes regulatory ambiguity for sponsors—especially those new to Australia or APAC.
Q: Looking ahead, what excites you most about PCI Melbourne’s future?
Michele Stokes:
What excites me most is PCI’s ability to support products end-to-end—from early clinical supply through development, manufacturing, and ultimately commercial packaging.
As PCI continues to expand across APAC, Melbourne has the opportunity to play a central role in helping sponsors not just run trials in the region, but build genuinely global development strategies—without needing a physical footprint everywhere.
Q: If sponsors take away one message about PCI Melbourne, what should it be?
Michele Stokes:
Distance and time zones should never be a barrier to confidence.
Between our global integration, experienced teams, and platforms like Bridge, sponsors have continuous visibility and control over their clinical supply—24/7. PCI Melbourne isn’t “far away”; it’s fully connected.